A Combination HIV Reporter Virus System for Measuring Post-entry Event Efficiency and Viral Outcome in Primary CD4+ T Cell Subsets

Overview

Journal J Virol Methods

Specialty Microbiology

Date 2013 Sep 13

PMID 24025341

Citations 10

Authors

Carisa A Tilton

Caroline O Tabler

Mark B Lucera

Samantha L Marek

Aiman A Haqqani

John C Tilton

Affiliations

Soon will be listed here.

Abstract

Fusion between the viral membrane of human immunodeficiency virus (HIV) and the host cell marks the end of the HIV entry process and the beginning of a series of post-entry events including uncoating, reverse transcription, integration, and viral gene expression. The efficiency of post-entry events can be modulated by cellular factors including viral restriction factors and can lead to several distinct outcomes: productive, latent, or abortive infection. Understanding host and viral proteins impacting post-entry event efficiency and viral outcome is critical for strategies to reduce HIV infectivity and to optimize transduction of HIV-based gene therapy vectors. Here, we report a combination reporter virus system measuring both membrane fusion and viral promoter-driven gene expression. This system enables precise determination of unstimulated primary CD4+ T cell subsets targeted by HIV, the efficiency of post-entry viral events, and viral outcome and is compatible with high-throughput screening and cell-sorting methods.

Citing Articles

The HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release.

Tabler C, Wegman S, Chen J, Shroff H, Alhusaini N, Tilton J J Virol. 2022; 96(9):e0219821.

PMID: 35438536 PMC: 9093094. DOI: 10.1128/jvi.02198-21.

Immune Control of HIV.

Balasubramaniam M, Pandhare J, Dash C J Life Sci (Westlake Village). 2019; 1(1):4-37.

PMID: 31468033 PMC: 6714987.

Global phosphoproteomics of CCR5-tropic HIV-1 signaling reveals reprogramming of cellular protein production pathways and identifies p70-S6K1 and MK2 as HIV-responsive kinases required for optimal infection of CD4+ T cells.

Wiredja D, Tabler C, Schlatzer D, Li M, Chance M, Tilton J Retrovirology. 2018; 15(1):44.

PMID: 29970186 PMC: 6029029. DOI: 10.1186/s12977-018-0423-4.

High sensitivity detection and sorting of infectious human immunodeficiency virus (HIV-1) particles by flow virometry.

Bonar M, Tilton J Virology. 2017; 505:80-90.

PMID: 28235684 PMC: 5393045. DOI: 10.1016/j.virol.2017.02.016.

HIV signaling through CD4 and CCR5 activates Rho family GTPases that are required for optimal infection of primary CD4+ T cells.

Lucera M, Fleissner Z, Tabler C, Schlatzer D, Troyer Z, Tilton J Retrovirology. 2017; 14(1):4.

PMID: 28114951 PMC: 5259950. DOI: 10.1186/s12977-017-0328-7.

References

Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z . LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem. 2003; 278(35):33528-39. DOI: 10.1074/jbc.M303594200. View

Chun T, Fauci A . HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS. 2012; 26(10):1261-8. DOI: 10.1097/QAD.0b013e328353f3f1. View

Piatak Jr M, Saag M, Yang L, Clark S, Kappes J, Luk K . High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993; 259(5102):1749-54. DOI: 10.1126/science.8096089. View

Wilen C, Parrish N, Pfaff J, Decker J, Henning E, Haim H . Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol. 2011; 85(17):8514-27. PMC: 3165820. DOI: 10.1128/JVI.00736-11. View

Durand S, Nguyen X, Turpin J, Cordeil S, Nazaret N, Croze S . Tailored HIV-1 vectors for genetic modification of primary human dendritic cells and monocytes. J Virol. 2012; 87(1):234-42. PMC: 3536400. DOI: 10.1128/JVI.01459-12. View

Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E . SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011; 474(7353):654-7. PMC: 3595993. DOI: 10.1038/nature10117. View

Archin N, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis D . Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses. 2009; 25(2):207-12. PMC: 2853863. DOI: 10.1089/aid.2008.0191. View

Cavrois M, de Noronha C, Greene W . A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol. 2002; 20(11):1151-4. DOI: 10.1038/nbt745. View

Hrecka K, Hao C, Gierszewska M, Swanson S, Kesik-Brodacka M, Srivastava S . Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011; 474(7353):658-61. PMC: 3179858. DOI: 10.1038/nature10195. View

10.

Zhou Y, Zhang H, Siliciano J, Siliciano R . Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol. 2005; 79(4):2199-210. PMC: 546571. DOI: 10.1128/JVI.79.4.2199-2210.2005. View

11.

Zack J, Arrigo S, Weitsman S, Go A, Haislip A, Chen I . HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990; 61(2):213-22. DOI: 10.1016/0092-8674(90)90802-l. View

12.

Jager S, Cimermancic P, Gulbahce N, Johnson J, McGovern K, Clarke S . Global landscape of HIV-human protein complexes. Nature. 2011; 481(7381):365-70. PMC: 3310911. DOI: 10.1038/nature10719. View

13.

Wilen C, Tilton J, Doms R . HIV: cell binding and entry. Cold Spring Harb Perspect Med. 2012; 2(8). PMC: 3405824. DOI: 10.1101/cshperspect.a006866. View

14.

Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J . Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol. 2004; 78(4):1718-29. PMC: 369469. DOI: 10.1128/jvi.78.4.1718-1729.2004. View

15.

Heinzinger N, Bukrinsky M, Haggerty S, Ragland A, Kewalramani V, Lee M . The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A. 1994; 91(15):7311-5. PMC: 44389. DOI: 10.1073/pnas.91.15.7311. View

16.

Busschots K, De Rijck J, Christ F, Debyser Z . In search of small molecules blocking interactions between HIV proteins and intracellular cofactors. Mol Biosyst. 2008; 5(1):21-31. DOI: 10.1039/b810306b. View

17.

Doitsh G, Cavrois M, Lassen K, Zepeda O, Yang Z, Santiago M . Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010; 143(5):789-801. PMC: 3026834. DOI: 10.1016/j.cell.2010.11.001. View

18.

Siliciano R . What do we need to do to cure HIV infection. Top HIV Med. 2010; 18(3):104-8. View

19.

Finzi D, Hermankova M, Pierson T, Carruth L, Buck C, Chaisson R . Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278(5341):1295-300. DOI: 10.1126/science.278.5341.1295. View

20.

Bobadilla S, Sunseri N, Landau N . Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein. Gene Ther. 2012; 20(5):514-20. PMC: 4105013. DOI: 10.1038/gt.2012.61. View